Products with Anti-prostatic disease bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4133 | Grandifloroside |
| 1. Grandifloroside shows good antioxidative and potent anti-inflammatory activities, it also exhibits potent inhibitory activity against TNF-α and 5α-reductase, suggests that it might be developed as a source of potent anti-oxidative and anti-inflammatory agents and therapeutic agent for benign prostatic hypertrophy (BPH). | |
| BCN5024 | Fisetin |
| Fisetin is an antimetastatic,antifungal, anti-inflammatory, antioxidant flavonoid, it has beneficial effect on periodontal disease, may via inhibiting MAPK activation and COX-2 expression without affecting cell viability. Fisetin can ameliorate photodamage by suppressing the mitogen-activated protein Kinase/Matrix metalloproteinase pathway and nuclear factor-κB pathways. Fisetin suppresses the accumulation of intracellular lipids by inhibiting GLUT4-mediated glucose uptake through inhibition of the mTOR-C/EBPα signaling in 3T3-L1 cells. | |
| BCN5280 | Nortrachelogenin |
| 1. (+)-Nortrachelogenin shows effects on the central nervous system producing depression in rabbits. 2. (-)-Nortrachelogenin can induce membrane disruption and caspase-dependent apoptosis. 3. Nortrachelogenin shows anti-plasmodium activity of 14.50 dg/ml. 4. Nortrachelogenin has anti-inflammatory properties. 5. Nortrachelogenin is a novel agent for prostate cancer therapy with ability to inhibit Akt membrane localization and activity as well as the activation of growth factor receptors, thereby efficiently synergizing with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), exposure. 6. (-)-Nortrachelogenin exerts its antibacterial effect by disorganizing and perturbing the cytoplasmic membrane. 7. (+)-Nortrachelogenin is moderately active against HIV-1 in vitro. 8. Nortrachelogenin shows moderate inhibiting activities on NF- κB signaling pathway induced by TNFα , with the IC50 value of 49.4 uM. | |
| BCN5521 | Atraric acid |
| Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes. | |
| BCN5868 | Sitostenone |
| 1. β-Sitostenone has antioxidation activity. 2. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia. | |
